Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03335280 · ClinicalTrials.gov registry record
68Ga-citrate PET/MR Imaging for Glioma
A clinical trial, sponsored by Susan Chang.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03335280 is a clinical trial that was terminated before completion, run by Susan Chang. The registered enrollment target is 2 participants.
The verdict
NCT03335280 was terminated before completion, sponsored by Susan Chang.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.
Interventions
- DRUG 68Ga-citrate PET/MR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2020-04-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03335280
The ClinicalTrials.gov registry entry for NCT03335280 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Susan Chang, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 68Ga-citrate PET/MR is the first listed.
NCT03335280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03335280 about?
NCT03335280 is a clinical study titled "68Ga-citrate PET/MR Imaging for Glioma". This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positro...
What is the current status of trial NCT03335280?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-02-26. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT03335280?
The interventions under investigation include: 68Ga-citrate PET/MR (DRUG).
Who is sponsoring clinical trial NCT03335280?
This trial is sponsored by Susan Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.